Kusajili – Clinical trials directory

Result of your search per sponsor: Beaufour Ipsen Pharma S.A.S

Woman and Man Max 99 years
Beaufour Ipsen Pharma S.A.S Update Il y a 4 ans

A phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients with upper back myofascial pain syndrome (MPS) To compare the efficacy of a single application of Dysport (100, 300 or 500 units) injected into 3 to 6 trigger points (TPs) located in the upper back musculature of adults with (MPS) with placebo

Country None
organs None
Specialty None

Closed trial

More information